91 related articles for article (PubMed ID: 16815068)
1. Establishment of a new cell line inducibly expressing HIV-1 protease for performing safe and highly sensitive screening of HIV protease inhibitors.
Fuse T; Watanabe K; Kitazato K; Kobayashi N
Microbes Infect; 2006 Jun; 8(7):1783-9. PubMed ID: 16815068
[TBL] [Abstract][Full Text] [Related]
2. Non-infectious fluorimetric assay for phenotyping of drug-resistant HIV proteinase mutants.
Majerová-Uhlíková T; Dantuma NP; Lindsten K; Masucci MG; Konvalinka J
J Clin Virol; 2006 May; 36(1):50-9. PubMed ID: 16527535
[TBL] [Abstract][Full Text] [Related]
3. Intrinsic activity of human immunodeficiency virus type 1 protease heterologous fusion proteins in mammalian cells.
Arrigo SJ; Haines JK; Huffman KM
DNA Cell Biol; 1995 Jan; 14(1):15-23. PubMed ID: 7832989
[TBL] [Abstract][Full Text] [Related]
4. A human immunodeficiency virus type 1 protease biosensor assay using bioluminescence resonance energy transfer.
Hu K; Clément JF; Abrahamyan L; Strebel K; Bouvier M; Kleiman L; Mouland AJ
J Virol Methods; 2005 Sep; 128(1-2):93-103. PubMed ID: 15951029
[TBL] [Abstract][Full Text] [Related]
5. Development of A Fission Yeast Cell-Based Platform for High Throughput Screening of HIV-1 Protease Inhibitors.
Benko Z; Zhang J; Zhao RY
Curr HIV Res; 2019; 17(6):429-440. PubMed ID: 31782368
[TBL] [Abstract][Full Text] [Related]
6. Structural Basis of Why Nelfinavir-Resistant D30N Mutant of HIV-1 Protease Remains Susceptible to Saquinavir.
Prashar V; Bihani SC; Ferrer JL; Hosur MV
Chem Biol Drug Des; 2015 Sep; 86(3):302-8. PubMed ID: 25487655
[TBL] [Abstract][Full Text] [Related]
7. Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.
Friedler A; Blumenzweig I; Baraz L; Steinitz M; Kotler M; Gilon C
J Mol Biol; 1999 Mar; 287(1):93-101. PubMed ID: 10074409
[TBL] [Abstract][Full Text] [Related]
8. Sensitive genetic screen for protease activity based on a cyclic AMP signaling cascade in Escherichia coli.
Dautin N; Karimova G; Ullmann A; Ladant D
J Bacteriol; 2000 Dec; 182(24):7060-6. PubMed ID: 11092869
[TBL] [Abstract][Full Text] [Related]
9. Proteolytic activity of human immunodeficiency virus Vpr- and Vpx-protease fusion proteins.
Wu X; Liu H; Xiao H; Kappes JC
Virology; 1996 May; 219(1):307-13. PubMed ID: 8623547
[TBL] [Abstract][Full Text] [Related]
10. [Establishment of a microbial assay for screening anti-human immunodeficiency virus type-1 protease inhibitors].
Leng Q; Tao P; Wang L; Gao Q
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1999 Apr; 21(2):140-5. PubMed ID: 12569671
[TBL] [Abstract][Full Text] [Related]
11. A non-infectious cell-based phenotypic assay for the assessment of HIV-1 susceptibility to protease inhibitors.
Buzon MJ; Erkizia I; Pou C; Minuesa G; Puertas MC; Esteve A; Castello A; Santos JR; Prado JG; Izquierdo-Useros N; Pattery T; Van Houtte M; Carrasco L; Clotet B; Ruiz L; Martinez-Picado J
J Antimicrob Chemother; 2012 Jan; 67(1):32-8. PubMed ID: 21994909
[TBL] [Abstract][Full Text] [Related]
12. Protocol for a mammalian cell-based assay for monitoring the HIV-1 protease activity.
Rajakuberan C; Hilton BJ; Wolkowicz R
Methods Mol Biol; 2012; 903():393-405. PubMed ID: 22782834
[TBL] [Abstract][Full Text] [Related]
13. Cell-based fluorescence assay for human immunodeficiency virus type 1 protease activity.
Lindsten K; Uhlíková T; Konvalinka J; Masucci MG; Dantuma NP
Antimicrob Agents Chemother; 2001 Sep; 45(9):2616-22. PubMed ID: 11502538
[TBL] [Abstract][Full Text] [Related]
14. A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
Leonis G; Steinbrecher T; Papadopoulos MG
J Chem Inf Model; 2013 Aug; 53(8):2141-53. PubMed ID: 23834142
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 Vif-derived peptide inhibits drug-resistant HIV proteases.
Blumenzweig I; Baraz L; Friedler A; Danielson UH; Gilon C; Steinitz M; Kotler M
Biochem Biophys Res Commun; 2002 Apr; 292(4):832-40. PubMed ID: 11944889
[TBL] [Abstract][Full Text] [Related]
16. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
Kozísek M; Bray J; Rezácová P; Sasková K; Brynda J; Pokorná J; Mammano F; Rulísek L; Konvalinka J
J Mol Biol; 2007 Dec; 374(4):1005-16. PubMed ID: 17977555
[TBL] [Abstract][Full Text] [Related]
17. Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo.
Ermolieff J; Lin X; Tang J
Biochemistry; 1997 Oct; 36(40):12364-70. PubMed ID: 9315877
[TBL] [Abstract][Full Text] [Related]
18. In vitro synthesis of enzymatically active HIV-1 protease for rapid phenotypic resistance profiling.
Hoffmann D; Buchberger B; Nemetz C
J Clin Virol; 2005 Apr; 32(4):294-9. PubMed ID: 15780808
[TBL] [Abstract][Full Text] [Related]
19. Understanding the HIV-1 protease nelfinavir resistance mutation D30N in subtypes B and C through molecular dynamics simulations.
Soares RO; Batista PR; Costa MG; Dardenne LE; Pascutti PG; Soares MA
J Mol Graph Model; 2010 Sep; 29(2):137-47. PubMed ID: 20541446
[TBL] [Abstract][Full Text] [Related]
20. Impedance method for detecting HIV-1 protease and screening for its inhibitors using ferrocene-peptide conjugate/Au nanoparticle/single-walled carbon nanotube modified electrode.
Mahmoud KA; Luong JH
Anal Chem; 2008 Sep; 80(18):7056-62. PubMed ID: 18707132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
